Munoh Kenne Foma: 8 Major Oncology Studies That Could Reshape Cancer Care

Munoh Kenne Foma, Hematologist and Oncologist at Presbyterian Healthcare Services, shared on LinkedIn:

”ESMO 2026: Eight Major Oncology Studies That Could Reshape Cancer Care!

The ESMO 2026 Congress in Madrid delivered an exceptional week of oncology research, including major survival breakthroughs, a new FDA approval, and important findings published in the New England Journal of Medicine.

My Oncology Weekly Brief (October 24-31, 2026) highlights eight essential studies every oncology professional should read.

My top three reading priorities:

TALAPRO-3 | Prostate Cancer: FDA approval of talazopario + enzalutamide for HRR-mutated metastatic hormone-sensitive prostate cancer (PFS HR 0.48).

TALAPRO-3 at ESMO 2026: Prognostic Utility of ctDNA Tumour Fraction in mCSPC

DeLLphi-305 | Small Cell Lung Cancer: Tarlatamab + durvalumab delivered a remarkable overall survival improvement: 21.1 vs 12.7 months (HR 0.42).

DeLLphi-305: Tarlatamab–Durvalumab Redefines First-Line Maintenance in Extensive-Stage SCLC

VOLGA | Bladder Cancer: Perioperative durvalumab + enfortumab vedotin significantly improved event-free and overall survival in cisplatin-ineligible muscle-invasive disease.

VOLGA at ESMO 2026: Perioperative Durvalumab With or Without Tremelimumab Plus Enfortumab Vedotin in MIBC

Five additional studies deserve attention:

SAFFRON: Osimertinib + savolitinib targets MET-mediated resistance in EGFR-mutant NSCLC.

SAFFRON Phase III: Osimertinib Plus Savolitinib Significantly Improves Progression-Free and Overall Survival in MET-Driven EGFR-Mutated NSCLC

KRASCENDO-1: Divarasib demonstrates superior survival versus established KRAS G12C inhibitors.

Krascendo 1 Phase III: Divarasib Significantly Improves Overall Survival and Progression-Free Survival Versus Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC

INTerpath-001: Personalized mRNA cancer vaccines advance immunotherapy in high-risk melanoma.

INTerpath-001 Trial: Personalized mRNA Cancer Vaccine in High-Risk Melanoma

NATALEE: Adjuvant ribociclib demonstrates encouraging long-term overall survival benefit in early breast cancer.

NATALEE: Ribociclib Delivers Overall Survival Benefit at 6 Years in HR+/HER2− Early Breast Cancer

IROCAS: An important negative trial showing that more intensive adjuvant chemotherapy does not necessarily improve outcomes.

IROCAS at ESMO 2026: mFOLFIRINOX vs mFOLFOX6 in High-Risk Stage III Colon Cancer

My central takeaway: The future of cancer care is not simply about more treatment. It is about delivering the right treatment to the right patient, guided by molecular biomarkers, meaningful survival benefits, and acceptable toxicity.

I invite my colleagues in oncology, hematology, surgery, radiation oncology, pathology, and cancer research to review the attached flyer for the key results and clinical implications.

Which ESMO 2026 study do you believe will have the greatest impact on clinical practice?

Evidence. Care. Hope.”